329 related articles for article (PubMed ID: 31859176)
1. Serum phosphate: Does it more closely reflect the true state of acromegaly?
Xie T; Tian P; Wu S; Zhang X; Liu T; Gu Y; Sun C; Hu F
J Clin Neurosci; 2020 Jan; 71():26-31. PubMed ID: 31859176
[TBL] [Abstract][Full Text] [Related]
2. Revisiting the Role of Insulin-like Growth Factor-1 Measurement After Surgical Treatment of Acromegaly.
Jung IH; Choi S; Ku CR; Lee SG; Lee EJ; Kim SH; Kim EH
J Clin Endocrinol Metab; 2021 Jun; 106(7):e2589-e2599. PubMed ID: 33738470
[TBL] [Abstract][Full Text] [Related]
3. Body mass index and insulin-like growth factor 1 as risk factors for discordant growth hormone and insulin-like growth factor 1 levels following pituitary surgery in acromegaly.
Zhang S; Li Y; Guo X; Gao L; Lian W; Yao Y; Feng M; Bao X; Wang R; Xing B
J Formos Med Assoc; 2018 Jan; 117(1):34-41. PubMed ID: 28341329
[TBL] [Abstract][Full Text] [Related]
4. Low insulin resistance after surgery predicts poor GH suppression one year after complete resection for acromegaly: a retrospective study.
Edo N; Morita K; Suzuki H; Takeshita A; Miyakawa M; Fukuhara N; Nishioka H; Yamada S; Takeuchi Y
Endocr J; 2016 May; 63(5):469-77. PubMed ID: 26949262
[TBL] [Abstract][Full Text] [Related]
5. Clinical indicators of biochemical remission in acromegaly: does incomplete disease control always mean therapeutic failure?
Damjanovic SS; Neskovic AN; Petakov MS; Popovic V; Macut D; Vukojevic P; Joksimovic MM
Clin Endocrinol (Oxf); 2005 Apr; 62(4):410-7. PubMed ID: 15807870
[TBL] [Abstract][Full Text] [Related]
6. Acromegaly.
Scacchi M; Cavagnini F
Pituitary; 2006; 9(4):297-303. PubMed ID: 17077948
[TBL] [Abstract][Full Text] [Related]
7. Postoperative GH and Degree of Reduction in IGF-1 Predicts Postoperative Hormonal Remission in Acromegaly.
Cardinal T; Collet C; Wedemeyer M; Singer PA; Weiss M; Zada G; Carmichael JD
Front Endocrinol (Lausanne); 2021; 12():743052. PubMed ID: 34867787
[TBL] [Abstract][Full Text] [Related]
8. Postoperative persistent thyrotrophin releasing hormone-induced growth hormone release predicts recurrence in patients with acromegaly.
Biermasz NR; Smit JW; van Dulken H; Roelfsema F
Clin Endocrinol (Oxf); 2002 Mar; 56(3):313-9. PubMed ID: 11940042
[TBL] [Abstract][Full Text] [Related]
9. Utility of baseline serum phosphorus levels for predicting remission in acromegaly patients.
Yalin GY; Tanrikulu S; Gul N; Uzum AK; Aral F; Tanakol R
J Endocrinol Invest; 2017 Aug; 40(8):867-874. PubMed ID: 28357781
[TBL] [Abstract][Full Text] [Related]
10. The utility of oral glucose tolerance testing for diagnosis and assessment of treatment outcomes in 166 patients with acromegaly.
Carmichael JD; Bonert VS; Mirocha JM; Melmed S
J Clin Endocrinol Metab; 2009 Feb; 94(2):523-7. PubMed ID: 19033371
[TBL] [Abstract][Full Text] [Related]
11. Paradoxical GH Increase During OGTT Is Associated With First-Generation Somatostatin Analog Responsiveness in Acromegaly.
Scaroni C; Albiger N; Daniele A; Dassie F; Romualdi C; Vazza G; Regazzo D; Ferraù F; Barresi V; Maffeis V; Gardiman MP; Cannavò S; Maffei P; Ceccato F; Losa M; Occhi G
J Clin Endocrinol Metab; 2019 Mar; 104(3):856-862. PubMed ID: 30285115
[TBL] [Abstract][Full Text] [Related]
12. Relationships between insulin-like growth factor-1 levels and growth hormone concentrations during diurnal profiles and following oral glucose in acromegaly.
Dobrashian RD; O'Halloran DJ; Hunt A; Beardwell CG; Shalet SM
Clin Endocrinol (Oxf); 1993 Jun; 38(6):589-93. PubMed ID: 8334745
[TBL] [Abstract][Full Text] [Related]
13. Assessment of disease activity in treated acromegalic patients using a sensitive GH assay: should we achieve strict normal GH levels for a biochemical cure?
Costa AC; Rossi A; Martinelli CE; Machado HR; Moreira AC
J Clin Endocrinol Metab; 2002 Jul; 87(7):3142-7. PubMed ID: 12107214
[TBL] [Abstract][Full Text] [Related]
14. Changing patterns of insulin-like growth factor-I and glucose-suppressed growth hormone levels after pituitary surgery in patients with acromegaly.
Espinosa-de-los-Monteros AL; Mercado M; Sosa E; Lizama O; Guinto G; Lopez-Felix B; Garcia O; Hernández I; Ovalle A; Mendoza V
J Neurosurg; 2002 Aug; 97(2):287-92. PubMed ID: 12186455
[TBL] [Abstract][Full Text] [Related]
15. Discordant GH and IGF-1 Results in Treated Acromegaly: Impact of GH Cutoffs and Mean Values Assessment.
Campana C; Cocchiara F; Corica G; Nista F; Arvigo M; Amarù J; Rossi DC; Zona G; Ferone D; Gatto F
J Clin Endocrinol Metab; 2021 Mar; 106(3):789-801. PubMed ID: 33236108
[TBL] [Abstract][Full Text] [Related]
16. The PPAR-gamma activator rosiglitazone fails to lower plasma growth hormone and insulin-like growth factor-1 levels in patients with acromegaly.
Bastemir M; Akin F; Yaylali GF
Neuroendocrinology; 2007; 86(2):119-23. PubMed ID: 17671378
[TBL] [Abstract][Full Text] [Related]
17. Long-term follow-up results of postoperative radiotherapy in 36 patients with acromegaly.
Biermasz NR; van Dulken H; Roelfsema F
J Clin Endocrinol Metab; 2000 Jul; 85(7):2476-82. PubMed ID: 10902796
[TBL] [Abstract][Full Text] [Related]
18. MANAGEMENT OF ENDOCRINE DISEASE: Etiology and outcome of acromegaly in patients with a paradoxical GH response to glucose.
Hage M; Janot C; Salenave S; Chanson P; Kamenický P
Eur J Endocrinol; 2021 May; 184(6):R261-R268. PubMed ID: 33830942
[TBL] [Abstract][Full Text] [Related]
19. Significance of "abnormal" nadir growth hormone levels after oral glucose in postoperative patients with acromegaly in remission with normal insulin-like growth factor-I levels.
Freda PU; Nuruzzaman AT; Reyes CM; Sundeen RE; Post KD
J Clin Endocrinol Metab; 2004 Feb; 89(2):495-500. PubMed ID: 14764751
[TBL] [Abstract][Full Text] [Related]
20. Predicting long-term remission by measuring immediate postoperative growth hormone levels and oral glucose tolerance test in acromegaly.
Kim EH; Oh MC; Lee EJ; Kim SH
Neurosurgery; 2012 May; 70(5):1106-13; discussion 1113. PubMed ID: 22067418
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
